Topical Mucosal Vaccination with Angiotensin (1-7) and Feline Immunodeficiency Virus Induces Secretory IgA ResponsesRobert A. Larsen1, Kathleen E. Rodgers2, W. Martin Kast2, Diane Da Silva2, Rosa Altomstone1, Christopher Meeks2, Gere S. diZerga2 and John M. Leedom1*
- *Corresponding Author:
- John M. Leedom
Department of Medicine (Infectious Diseases)
LAC+USC Medical Center
IRD Building, 2020 Zonal Ave. - Room 430
Los Angeles, CA 90033, USA
Tel: (323) 226-7504
Fax: (323) 226-2308
Received date: October 28, 2014; Accepted date: March 20, 2015; Published date:March 22,2015
Citation: Larsen RA, Rodgers KE, Kast WM, Silva DD, Altomstone R, et al. (2015) Topical Mucosal Vaccination with Angiotensin (1-7) and Feline Immunodeficiency Virus Induces Secretory IgA Responses. J Med Microb Diagn 4:179. doi: 10.4172/2161-0703.1000179
Copyright: © 2015 Larsen RA, et al This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Pre-existing mucosal generated secretory IgA antibodies may prevent transmission of HIV. The present study aimed to characterize mucosal antibodies generated following topical vaccination with a novel mucosal adjuvant, angiotensin (1-7), in combination with a killed feline immunodeficiency virus (FIV) vaccine used as a model antigen.
Methods: Female outbred cats were vaccinated with Fel-O-Vax FIV vaccine agent combined with increasing concentrations of angiotensin (1-7) [A (1-7)] applied topically to oral, vaginal and rectal surfaces weekly for six weeks. Control animals received intramuscular vaccinations with the Fel-O-Vax FIV alone or with A (1-7). Mucosal secretions were evaluated for antibody responses against FIV-p24 antigen or HIV-gp120 antigen.
Results: Topical application of whole killed FIV virus with A (1-7) induced substantial secretory IgA (SIgA)-antigp120 antibodies in oral, vaginal and rectal secretions across a wide ranges of A (1-7) dose levels. Intramuscular vaccination of FIV antigen with A (1-7) induced high levels of SIgA-anti-gp120 antibodies at vaginal and rectal sites. The topical application vaccination strategy elicited only very weak systemic immune responses.
Conclusion: Angiotensin (1-7) is a potent mucosal vaccine adjuvant.